New Results
A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activation
Dagim Shiferaw Tadele, Joseph Robertson, Richard Crispin, Maria C. Herrera, Marketa Chlubnova, Laure Piechaczyk, Pilar Ayuda-Durán, Sachin Kumar Singh, Tobias Gedde-Dahl, Yngvar Fløisand, Jørn Skavland, Jørgen Wesche, Bjørn-Tore Gjertsen, View ORCID ProfileJorrit M. Enserink
doi: https://doi.org/10.1101/2020.05.16.089755
Dagim Shiferaw Tadele
1Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
3Faculty of Medicine, University of Oslo, Oslo, Norway
Joseph Robertson
1Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
Richard Crispin
1Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
Maria C. Herrera
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
4Section for Biochemistry and Molecular Biology, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Marketa Chlubnova
1Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
Laure Piechaczyk
1Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
3Faculty of Medicine, University of Oslo, Oslo, Norway
Pilar Ayuda-Durán
1Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
Sachin Kumar Singh
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
5Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
Tobias Gedde-Dahl
6Department of Hematology, Oslo University Hospital, Oslo, Norway
Yngvar Fløisand
6Department of Hematology, Oslo University Hospital, Oslo, Norway
Jørn Skavland
7Department of Hematology, Haukeland University Hospital, Bergen, Norway
Jørgen Wesche
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
5Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
Bjørn-Tore Gjertsen
7Department of Hematology, Haukeland University Hospital, Bergen, Norway
Jorrit M. Enserink
1Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
4Section for Biochemistry and Molecular Biology, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Article usage
Posted July 18, 2020.
A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activation
Dagim Shiferaw Tadele, Joseph Robertson, Richard Crispin, Maria C. Herrera, Marketa Chlubnova, Laure Piechaczyk, Pilar Ayuda-Durán, Sachin Kumar Singh, Tobias Gedde-Dahl, Yngvar Fløisand, Jørn Skavland, Jørgen Wesche, Bjørn-Tore Gjertsen, Jorrit M. Enserink
bioRxiv 2020.05.16.089755; doi: https://doi.org/10.1101/2020.05.16.089755
A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activation
Dagim Shiferaw Tadele, Joseph Robertson, Richard Crispin, Maria C. Herrera, Marketa Chlubnova, Laure Piechaczyk, Pilar Ayuda-Durán, Sachin Kumar Singh, Tobias Gedde-Dahl, Yngvar Fløisand, Jørn Skavland, Jørgen Wesche, Bjørn-Tore Gjertsen, Jorrit M. Enserink
bioRxiv 2020.05.16.089755; doi: https://doi.org/10.1101/2020.05.16.089755
Subject Area
Subject Areas
- Biochemistry (11703)
- Bioengineering (8718)
- Bioinformatics (29127)
- Biophysics (14930)
- Cancer Biology (12048)
- Cell Biology (17353)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14143)
- Epidemiology (2067)
- Evolutionary Biology (18266)
- Genetics (12219)
- Genomics (16765)
- Immunology (11841)
- Microbiology (28003)
- Molecular Biology (11551)
- Neuroscience (60804)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3229)
- Physiology (4939)
- Plant Biology (10383)
- Synthetic Biology (2877)
- Systems Biology (7333)
- Zoology (1642)